![](https://endpts.com/wp-content/uploads/2021/06/Michael-Yang-ViaCyte-tile-scaled.jpg)
Michael Yang, ViaCyte CEO
‘Disappointing’ ViaCyte data raise questions about future of company’s attempted diabetes cure
Over the last 20 years, ViaCyte — under one name or another — has pursued one of the most audacious goals in biotech: a cure for type …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.